Category: Gynecology > HPV / cervical screening
Is the EGCG / folate / B12 / hyaluronic acid research in PCERV ads a trial of this jar?
No. PMID 36983172 and 40508059 studied a four-molecule Italian oral combo at specified milligram doses. PCERV ads also list pomegranate, graviola, and two lactobacilli. That literature is not an RCT of this Lediiso jar. Probiotic papers (PMID 31207095, 31538342) are microbiome context, not this SKU.
Red flags: when to see a clinician — not chase a green-tea extract
Bleeding after sex, postmenopausal bleeding, unexplained pelvic pain, foul discharge, fever, CIN2/CIN3 or cancer, a missed colposcopy visit, or pregnancy plus an abnormal screen — see a clinician now. Do not decide from ad percentages.
Management:
ASCCP.
Screening:
NCI cervical screening.
- Bleeding after sex — not an EGCG-clip layer
- Postmenopausal bleeding — assess; do not chase extracts
- Unexplained pelvic pain, foul discharge, or fever
- CIN2 / CIN3 or cancer — a different layer from Italian papers; see
HPV16/18 CIN1 to CIN3 and LEEP - Missed colposcopy, or pregnancy plus an abnormal result — do not wait on a jar
How do the papers in ads differ from the PCERV jar?
The Italian four-molecule oral formula is not an RCT of this Thai SKU.
Sales copy may lift clearance figures. This page does not paste those figures as Lediiso results, because they come from open/single-arm work on another formula, and Thai ads add extra ingredients.
Aragona 2023: 12-week pilot, n=40
Aragona et al. (PMID 36983172)
studied oral EGCG 200 mg + folic acid 400 µg + vitamin B12 1 mg + hyaluronic acid 50 mg for 12 weeks in 40 participants (treated arm 17 of 20 cleared; untreated control, not placebo).
The authors said a larger placebo RCT is needed.
That is not a PCERV jar trial and not the 6-month course on Thai clips.
2025 Italian paper: single-arm 6 months, n=106 — same four molecules, not this jar
PMID 40508059
(PMC12155352)
is a single-arm, open study of the same four molecules for 6 months, n=106.
That paper reported 91 of 106 for that formula (single-arm — not Lediiso PCERV results).
It is not a parallel placebo RCT, and it did not study pomegranate, graviola, or two probiotics as part of that set.
Aragona 2023 (PMID 36983172): treated arm 17 of 20 cleared in a 12-week open pilot (untreated control, not placebo; authors asked for a larger placebo RCT).
Porcaro 2025 (PMID 40508059): single-arm n=106 over 6 months reported 91 of 106 (85.8%) for that four-molecule formula.
Trial doses: EGCG 200 mg + folate 400 µg + B12 1 mg + HA 50 mg — this page does not invent the Thai jar’s milligrams.
Bars are Italian-formula counts, not Lediiso PCERV results.
Pomegranate, graviola, and two lactobacilli — were they in the Italian papers?
They were not in the four-molecule set studied in PMID 36983172 and 40508059.
Lediiso PCERV marketplace copy often adds pomegranate extract, graviola/soursop, Lactobacillus rhamnosus, and Lactobacillus crispatus, plus white wood-ear mushroom marketed as a hyaluronic-acid source.
Sharing some molecule names does not make the jar the Italian trial formula.
Read the label in your hand; do not invent a dose from a clip.
L. crispatus and microbiome papers — context, not this SKU
PMID 31207095
summarizes L. crispatus and vaginal health.
PMID 31538342
links vaginal microbiome patterns with HPV persistence.
Both are context layers — not a Lediiso jar trial, and not a substitute for HPV vaccine or Pap.
Read
HPV probiotics and supplements.
A supplement does not replace screening — see
Do not skip screening.
Get a severity-level analysis from our Advisory team
Get a severity-level analysis and personalized guidance from our Advisory team
Layer comparison: Italian four-molecule papers / L. crispatus literature / PCERV jar / screening–vaccine
A pilot and a single-arm study of another formula are not this jar’s label — HPV vaccine and ASCCP sit on a different layer.
| Source | Form | Population / duration | What that work studied | Why it is not this jar |
|---|---|---|---|---|
| Aragona 2023 four-molecule combo | Oral EGCG 200 mg + folate 400 µg + B12 1 mg + HA 50 mg | n=40 · 12 weeks · pilot | Italian formula — PMID 36983172; authors asked for a larger placebo RCT | Different label; no pomegranate, graviola, or two probiotics |
| 2025 Italian same four molecules | Oral same four molecules | n=106 · 6 months · single-arm / open | Clearance figures for that formula — PMID 40508059 | Not an RCT of Lediiso; do not paste those figures as jar results |
| L. crispatus / microbiome literature | Vaginal-health context — not a jar | Not users of this Thai SKU | PMID 31207095; HPV persistence PMID 31538342 | Microbiome context is not a PCERV RCT |
| PCERV jar (Lediiso) | Oral dietary supplement | Marketplace copy often says ~6 months — read the label | No public RCT tying ad figures to this SKU | It is this product — but not a drug and not Aragona 2023 / 2025 single-arm |
| HPV vaccine / Pap / colposcopy–LEEP | Clinic layer per WHO, USPSTF, ASCCP | Per visit and criteria — not a jar course | Prevention, screening, CIN management | Different layer; do not skip because of Italian papers |
Frequently asked questions
Is the EGCG / folate / B12 / hyaluronic acid research in ads an RCT of Lediiso PCERV?
No. PMID 36983172 and 40508059 studied a four-molecule Italian oral combo at specified milligram doses. That is not an RCT of the Thai jar whose ads also list pomegranate, graviola, and two lactobacilli.
What did Aragona 2023 (PMID 36983172) study, and for how long?
A pilot of oral EGCG 200 mg + folic acid 400 µg + B12 1 mg + hyaluronic acid 50 mg for 12 weeks, n=40 (treated arm 17 of 20 cleared; untreated control, not placebo). The authors said a larger placebo RCT is needed. It is not the PCERV jar.
Is the 2025 Italian paper (PMID 40508059) an RCT of this jar?
No. It is a single-arm, open study of the same four molecules for 6 months, n=106, reporting 91 of 106 (85.8%) for that formula — not a parallel placebo RCT and not this Thai SKU.
Why do pomegranate, graviola, and two lactobacilli make a different formula?
Neither Italian paper studied pomegranate, graviola, L. rhamnosus, or L. crispatus as a set with this jar. Marketplace copy that adds those ingredients is not the four-molecule paper formula.
Does the L. crispatus paper (PMID 31207095) prove this jar clears HPV?
No. PMID 31207095 is vaginal-health context for L. crispatus, not a Lediiso jar trial, and it does not replace screening.
Is the microbiome–HPV persistence paper (PMID 31538342) a PCERV trial?
No. PMID 31538342 describes vaginal microbiome associations with HPV persistence. That is context, not an RCT of this SKU.
Can Italian clearance figures in ads be used as results for this jar?
No. Aragona 2023 (PMID 36983172) reported 17 of 20 in the treated arm (12-week open pilot); Porcaro 2025 (PMID 40508059) reported 91 of 106 in a 6-month single-arm study — both are Italian-formula results, not Lediiso PCERV.
Does a Thai FDA (อย.) number mean the formula equals the Italian papers?
No. Read the label in your hand. This page does not invent a Thai FDA number. Supplement registration does not make the jar the trial formula in PMID 36983172 or 40508059.
Scientific mechanism (author synthesis)
Sharing molecule names is not an RCT of a jar, and HPV persistence tracks immunity and the microbiome — not marketplace labels.
Asst. Prof. Dr. Norawit Raatpiboon
synthesizes that
PMID 36983172
is a 12-week n=40 pilot whose authors asked for a larger placebo RCT,
PMID 40508059
is a 6-month n=106 single-arm study of the same four molecules, and
PMID 31207095
plus
PMID 31538342
are vaginal context — not this SKU.
Clearance in 1–2 years per
CDC
is not a jar result.
Academic citations (E-E-A-T)
- Aragona et al. 2023 — oral EGCG 200 mg + folic acid 400 µg + B12 1 mg + HA 50 mg, 12 weeks, n=40 (PMID 36983172) — not PCERV
- 2025 Italian oral four-molecule single-arm, 6 months, n=106 (PMID 40508059) · PMC12155352 — not this Thai SKU
- L. crispatus and vaginal health (PMID 31207095) — microbiome context, not this jar
- Vaginal microbiome and HPV persistence (PMID 31538342) — not PCERV
- CDC — HPV about
- WHO — Human papillomavirus and cancer
- ACOG — Cervical cancer screening FAQ
- ASCCP — Management guidelines
Medical disclaimer
This article and its diagrams are general information from Well Wellness Thailand / dr9ohm.com — not a diagnosis, a prescription, or a results guarantee.
PCERV is a dietary supplement, not an HPV drug and not a cervical-cancer treatment.
Italian papers cited in ads are not an RCT of this jar. They do not replace HPV vaccine, Pap, HPV DNA testing, colposcopy, or LEEP.
Follow the dose on the label in your hand. This page does not invent a Thai FDA number.